Current Report · Items 9.01 · 8-K/A
SANGAMO THERAPEUTICS INC
SGMOQOTCEQUITYCurrent
Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2.1# Asset Purchase Agreement, dated June 22, 2026, by and among Sangamo…
Company context
Sangamo Therapeutics is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company is currently operating under court supervision in Chapter 11. To learn more, visit www.sangamo.com.
Current securities
Recent company filings
- Bankruptcy or Receivership · Completion of Acquisition or Disposition of AssetsSep 21, 2026
- Bankruptcy or Receivership · Completion of Acquisition or Disposition of Assets · Regulation FD DisclosureSep 8, 2026
- Entry into a Material Definitive Agreement · Bankruptcy or ReceivershipAug 28, 2026
- NT 10-Q filingAug 17, 2026
- SCHEDULE 13G/A filingAug 14, 2026
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Description
No.
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
2.1# Asset Purchase Agreement, dated June 22, 2026, by and among Sangamo Therapeutics, Inc., Merope Acquisition Sub, LLC, Eli Lilly and Company, and Sangamo Therapeutics UK Ltd., Sangamo Therapeutics France SAS, and Ceregene, Inc.
2.2# Asset Purchase Agreement, dated June 22, 2026, by and between Sangamo Therapeutics, Inc. and Astellas Gene Therapies, Inc.
104 Cover Page Interactive Data File (embedded within Inline XBRL document).
Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.